(Q41733398)

8 October 2017

1 reference

title

Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection (English)

1 reference

8 October 2017

1 reference

Perry CM

1

1 reference

8 October 2017

Noble S

series ordinal

2

1 reference

8 October 2017

publication date

1 March 1998

1 reference

8 October 2017

1 reference

8 October 2017

volume

55

1 reference

8 October 2017

issue

3

1 reference

8 October 2017

page(s)

461-486

1 reference

FDA warns of potential protease-inhibitor link to hyperglycaemia

8 October 2017

cites work

1 reference

12 December 2020

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

12 December 2020

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

12 December 2020

In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages

1 reference

12 December 2020

HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes

1 reference

12 December 2020

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

12 December 2020

Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2.

1 reference

12 December 2020

Rational approaches to resistance: using saquinavir

1 reference

12 December 2020

Saquinavir in the management of HIV infection.

1 reference

12 December 2020

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

12 December 2020

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

1 reference

12 December 2020

Rational design of peptide-based HIV proteinase inhibitors

1 reference

12 December 2020

British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee

1 reference

12 December 2020

Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex

1 reference

12 December 2020

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

1 reference

12 December 2020

HIV-1 protease inhibitors. A review for clinicians

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors

1 reference

12 December 2020

Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism

1 reference

12 December 2020

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

1 reference

12 December 2020

Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients

1 reference

12 December 2020

1 reference

12 December 2020

Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro

1 reference

12 December 2020

Protease inhibitors for HIV infection

1 reference

12 December 2020

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection

1 reference

12 December 2020

Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.

1 reference

12 December 2020

Sequential versus simultaneous combination antiretroviral regimens for the treatment of human immunodeficiency virus type 1 infection in vitro

1 reference

12 December 2020

Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase

1 reference

12 December 2020

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

1 reference

12 December 2020

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences

1 reference

12 December 2020

1 reference

12 December 2020

In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors

1 reference

12 December 2020

Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication

1 reference

12 December 2020

1 reference

12 December 2020

Photosensitivity due to saquinavir

1 reference

12 December 2020

A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection

1 reference

12 December 2020

10.2165/00003495-199855030-00014

Identifiers

DOI

1 reference

Dimensions Publication ID

8 October 2017

1027427498

0 references

1 reference